Completed PHASE4 INTERVENTIONAL NCT00159679

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions Diabetic Neuropathy, Painful

Interventions Pregabalin

Updated 7 times since 2017 Last updated: Jan 21, 2021 Started: Sep 30, 2004 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Diabetic Neuropathy, Painful, this trial is completed. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Feb 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Feb 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Boston, United States , Dallas, United States , Denver, United States , Duncansville, United States , Englewood, United States , Greenville, United States , Hot Springs, United States , Houston, United States , La Jolla, United States and 12 more locations